afa looks forward to work wh members of the subcommittee to address important issues raised in today's hearing, and in the long term to end devastation caused by alzheimer's disease. thank you. >> thank you, mr. hall. the mic on? might have to bring it closer. >> mr. chairman, chairma and staff, thank you for the opportunity to present testimony on this important topic. i'm marc cantillon, a practicing physician and a neuroscientist with 15 years in research and ug development and within the pharmaceutical industry. this is a nonprofit organization founded in 2005 by the fda and the arizona community in order to build collaborations that identify more reliable and efficient methods to test new medicines applied regulatory science. as you have heard, in spite of the exciting discoveries in research, we lack full translation. we lack new medicines that could significantly alter the course of the disease, and indeed, we've seen huge alzheimer's disease drug trials fail. nevertheless, there is reason for a renewed hope. across the hall in science is a proverb written that i'd like to quote